Stock Research for BLRX

BLRX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BLRX Stock Chart & Research Data

The BLRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BLRX Due diligence Resources & Stock Charts

The BLRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BLRX Detailed Price Forecast - CNN Money CNN View BLRX Detailed Summary - Google Finance
Yahoo View BLRX Detailed Summary - Yahoo! Finance Zacks View BLRX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View BLRX Trends & Analysis - Trade-Ideas Barrons View BLRX Major Holders - Barrons
NASDAQ View BLRX Call Transcripts - NASDAQ Seeking View BLRX Breaking News & Analysis - Seeking Alpha
Spotlight View BLRX Annual Report - CompanySpotlight.com OTC Report View BLRX OTC Short Report - OTCShortReport.com
TradeKing View BLRX Fundamentals - TradeKing Charts View BLRX SEC Filings - Bar Chart
WSJ View Historical Prices for BLRX - The WSJ Morningstar View Performance/Total Return for BLRX - Morningstar
MarketWatch View the Analyst Estimates for BLRX - MarketWatch CNBC View the Earnings History for BLRX - CNBC
StockMarketWatch View the BLRX Earnings - StockMarketWatch MacroAxis View BLRX Buy or Sell Recommendations - MacroAxis
Bullish View the BLRX Bullish Patterns - American Bulls Short Pains View BLRX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View BLRX Stock Mentions - StockTwits PennyStocks View BLRX Stock Mentions - PennyStockTweets
Twitter View BLRX Stock Mentions - Twitter Invest Hub View BLRX Investment Forum News - Investor Hub
Yahoo View BLRX Stock Mentions - Yahoo! Message Board Seeking Alpha View BLRX Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for BLRX - SECform4.com Insider Cow View Insider Transactions for BLRX - Insider Cow
CNBC View BLRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BLRX - OTC Markets
Yahoo View Insider Transactions for BLRX - Yahoo! Finance NASDAQ View Institutional Holdings for BLRX - NASDAQ


Stock Charts

FinViz View BLRX Stock Insight & Charts - FinViz.com StockCharts View BLRX Investment Charts - StockCharts.com
BarChart View BLRX Stock Overview & Charts - BarChart Trading View View BLRX User Generated Charts - Trading View


Latest Financial News for BLRX

Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)
Posted on Tuesday April 03, 2018

Moving Average Crossover Alert: BioLineRx Ltd. (BLRX)


Wired News – vTv Therapeutics Completed Phase-1b Study Evaluating TTP399 for Treatment of Type-1 Diabetes
Posted on Tuesday March 27, 2018

Stock Monitor: BioLine Rx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you ...


BioLineRx Announces Notice of Allowance From USPTO for Patent Covering AGI-134 - a Novel Immunotherapy for Treating Solid Tumors
Posted on Monday March 26, 2018

TEL AVIV, Israel, March 26, 2018 /PRNewswire/ --  BioLineRx Ltd. (BLRX) (BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that a Notice of Allowance has been issued by the United States Patent and Trademark Office (USPTO) for a patent application claiming the use of AGI-134, a novel immunotherapy compound, for the treatment of solid cancer tumors. This patent, when issued, will be valid until May 2035 with a possibility of up to five years patent term extension. Additional corresponding patent applications for AGI-134 are pending in Europe, Japan, China, Canada, Australia and Israel.


BioLineRx to Present at the 28th Annual Oppenheimer Healthcare Conference
Posted on Wednesday March 14, 2018

TEL AVIV, Israel , March 14, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...


Enter a stock symbol to view the stock details.